Beam Therapeutics Inc

Research Beam Therapeutics Inc (BEAM) on Bullrun: market cap USD 3.60B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerBEAM
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 3.60B
• Financial periodFY2025
• RevenueUSD 139.74M
• Revenue growth120.0%
• Net income-USD 79.99M
• Free cash flow-USD 360.05M

Valuation Snapshot

latest market cap is USD 3.60B.

About Beam Therapeutics Inc

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency;

Frequently asked questions

What is Beam Therapeutics Inc's market cap?

Beam Therapeutics Inc's market capitalization is USD 3.60B.

What does Beam Therapeutics Inc do?

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States.